Liver Research Centre, Division of Hepatology, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan; Division of Allergy, Asthma, and Rheumatology, Department of Paediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan; Clinical Informatics and Medical Statistics Research Centre, Chang Gung University, Taoyuan, Taiwan.
Department of Biomedical Sciences, Chang Gung University, Taoyuan, Taiwan; Metabolomics Core Laboratory, Healthy Aging Research Centre, Chang Gung University, Taoyuan, Taiwan; Clinical Phenome Centre, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
J Clin Lipidol. 2018 May-Jun;12(3):756-766. doi: 10.1016/j.jacl.2018.02.011. Epub 2018 Mar 2.
How hepatitis C virus (HCV)-associated lipid metabolic alterations recover after sustained virological response (SVR) remains elusive.
The aforementioned recovery pattern was investigated.
In a prospective cohort study of 438 chronic hepatitis C (CHC) patients with SVR after anti-HCV therapy, 164 sex- and age-matched genotype I (G1) and G2 patients underwent paired-serum liquid chromatography-tandem mass spectrometry analyses before and 24 weeks after therapy. Subjects without CHC served as controls (n = 100).
CHC patients had lower baseline lipid levels than controls. Among CHC patients, pre-therapy total cholesterol levels were positively associated with HCV RNA levels; G1 patients had higher pre-therapy HCV RNA levels than G2 patients. Repeated measures analysis of variance of CHC patients showed that lathosterol, lanosterol, total hydroxysphingomyelin, and total phosphatidylcholines levels, and total dicarboxyacylcarnitine/total acylcarnitine (indicators of ω-oxidation) and pre-β-lipoprotein ratios elevated 24 weeks after therapy compared with the levels before therapy. Levels of total lysophosphatidylcholines and α- and β-lipoprotein ratios decreased. Subgroup analyses showed elevated 7-dehydrocholesterol and lanosterol levels, particularly in G2 and male patients, who had broader spectra of altered phosphatidylcholines and acylcarnitines than G1 and female patients, respectively. Compared with controls, CHC patients had higher post-therapy levels of total lysophosphatidylcholines and hydroxysphingomyelins and ratios of total dicarboxyacylcarnitines/total acylcarnitines but lower cholesterol levels.
At 24 weeks after therapy, accelerated cholesterol biosynthesis, hepatic lipid export, ω-oxidation, and decreased systemic inflammation were noted in CHC patients with SVR, with greater efficiency in G2 and male patients. Regardless, HCV-associated lipid metabolic alterations required >24 weeks for restoration or were incompletely reversible after SVR.
慢性丙型肝炎病毒(HCV)相关的脂质代谢改变在获得持续病毒学应答(SVR)后如何恢复仍不清楚。
研究上述恢复模式。
在一项 438 例慢性丙型肝炎(CHC)患者抗病毒治疗后获得 SVR 的前瞻性队列研究中,164 例性别和年龄匹配的基因型 1(G1)和 G2 患者在治疗前和治疗后 24 周进行了配对血清液相色谱-串联质谱分析。未患 CHC 的受试者作为对照(n=100)。
CHC 患者的基线血脂水平低于对照组。在 CHC 患者中,治疗前总胆固醇水平与 HCV RNA 水平呈正相关;G1 患者的 HCV RNA 水平高于 G2 患者。CHC 患者的重复测量方差分析显示,治疗后 24 周,羊毛固醇、菜油固醇、总羟基神经酰胺和总磷脂酰胆碱以及总二羧基酰基辅酶 A/总酰基辅酶 A(ω-氧化的指标)和前-β-脂蛋白比值升高。总溶血磷脂酰胆碱和α-和β-脂蛋白比值降低。亚组分析显示,7-脱氢胆固醇和菜油固醇水平升高,尤其是在 G2 和男性患者中,他们的磷脂酰胆碱和酰基辅酶 A谱改变比 G1 和女性患者更广泛。与对照组相比,CHC 患者治疗后总溶血磷脂酰胆碱和羟基神经酰胺水平升高,总二羧基酰基辅酶 A/总酰基辅酶 A 比值升高,但胆固醇水平降低。
在治疗后 24 周时,CHC 患者 SVR 后观察到胆固醇生物合成加速、肝脂质输出、ω-氧化和全身炎症减轻,G2 和男性患者效率更高。然而,HCV 相关的脂质代谢改变需要>24 周才能恢复,或者在 SVR 后无法完全逆转。